Even treatment with the non-steroidal MR antagonist finerenone decreased the risk of CKD progression in patients with CKD and diabetes in the recent FIDELIO-DKD and FIGARO-DKD trials [15,16]. This evidence concerns the gene NR3C2 and chronic kidney disease.